THIENOPYRIDINES: PLATELET ADP RECEPTOR ANTAGONIST
AbstractAtherothrombotic disease is the result of atherosclerosis progression, and its clinical manifestations [acute coronary syndromes (ACS), stroke, etc). These events are mostly secondary to atherosclerotic plaque disruption and subsequent thrombus formation. Atherosclerosis prevention is mainly focused on the management of the so-called â€˜cardiovascular risk factorsâ€™; whereas thrombosis-related complications are mainly prevented and/or treated by antithrombotic therapies. The central role of platelets in the pathophysiology of arterial vascular disease has focused attention on the development of effective platelet inhibitor modalities to mitigate the clinical consequences of atherothrombotic disease. Aspirin has been the mainstay; the thienopyridines provide new opportunities for those patients who are intolerant, resistant or have failed aspirin, and for those who can derive greater beneï¬t from combined therapy. Thienopyridines (ticlopidine, clopidogrel etc.) are a class of ADP receptor/P2Y12 inhibitors used for their anti-platelet activity. The co-administration aspirin-clopidogrel results in enhancement of platelet inhibition, since they act via different platelet receptors. This article reviews the current antiplatelet agents in ACSs and role of thienopyridines as antiplatelet agents in management.
Download data is not yet available.
133 Views | 162 Downloads
How to Cite
Dangi G, Bele D, Sharma K. THIENOPYRIDINES: PLATELET ADP RECEPTOR ANTAGONIST. JDDT [Internet]. 25Oct.2011 [cited 30Nov.2020];1(1). Available from: http://jddtonline.info/index.php/jddt/article/view/7
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).